Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Name

Webedition CMS

Purpose

This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.

Name

econda

Purpose

Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Name	econda
Purpose	Statistics

Name

econda

Purpose

Statistics

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Name

YouTube

Purpose

Show YouTube content

Name

Twitter

Purpose

activate Twitter Feeds

Organizers

Initiated in 2004, and actively treating patients since 2005, the National Center for Tumor Diseases (NCT) Heidelberg was founded as an exceptional alliance between the German Cancer Research Center (DKFZ), Heidelberg University Medical School (HUMS) together with Heidelberg Medical Faculty and German Cancer Aid (Deutsche Krebshilfe). NCT is a comprehensive cancer center uniquely positioned to benefit from the wealth of DKFZ cancer research and the Heidelberg biomedical campus. NCT’s mission is two-fold: to provide optimal interdisciplinary oncology with current clinical therapies and to rapidly transfer scientific knowledge into clinical applications through comprehensive translational and preventive oncology. The new 5500 m² NCT Core Building has been completed in 2010.

NCT is the principal portal of entry for all oncology patients into the medical center, and the primary location of all oncology outpatient care. It integrates and supports all clinical and translational research activities of DKFZ and HUMS. DKFZ’s many scientific disciplines and interactions, including strategic partnerships with university medical centers and industry, provide a strong framework for NCT projects.

In 2012, approx. 10.000 newly diagnosed cancer patients were seen at NCT and more than 18.000 anti-tumor therapies were administered. With more than 54.000 out-patient visits p.a., patient numbers are steadily growing. 300 diagnostic, therapeutic and preventive clinical trials, including investigator initiated trials, were developed and conducted.

NCT pursues personalized oncology as a center-wide master strategy that coordinates all activities towards individualized cancer medicine, including patient-oriented genetics, proteomics, radiooncology, immunology and prevention. The recently established Heidelberg Center for Personalized Oncology (DKFZ-HIPO) forms a dedicated genomics, proteomics and bioinformatics platform of DKFZ, enabling excellent basic and translational research. Its clinical counterpart, the NCT Precision Oncology Program (NCT POP) combines molecular diagnostics, innovative therapeutics development, interdisciplinary patient care and prevention to define molecularly stratified patient cohorts and hypothesis-driven treatments. Towards this goal, the center aims to provide comprehensive high-throughput genetic and molecular analysis as a stratification tool for every NCT patient until 2015.